1-(二苯基甲基)-3-甲基吖丁啶 | 336182-51-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(二苯基甲基)-3-甲基吖丁啶
• 中文别名: 1-(二苯基甲基)-3-甲基氮杂丁烷
• 英文名称: 1-Benzhydryl-3-methylazetidine
• CAS: 336182-51-5
• 化学式: C₁₇H₁₉N
• 分子量: 237.34
• InChiKey: NBCXZRVQEDJOBK-UHFFFAOYSA-N

物化性质

• 熔点：
  46-48℃
• 沸点：
  317.6±11.0 °C(Predicted)
• 密度：
  1.058±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] TARGETING COMPOUNDS<br/>[FR] COMPOSÉS DE CIBLAGE
  申请人：ZAFGEN INC

  公开号：WO2019118612A1

  公开（公告）日：2019-06-20

  The disclosure provides, at least in part, liver, intestine and/or kidney-targeting compounds and their use in treating liver, intestine and/or kidney disorders, such as non-alcoholic steatohepatitis, alcoholic steatohepatitis, hepatocellular carcinoma, liver cirrhosis, and hepatitis B; and/or chronic kidney disease, glomerular disease such as IGA nephropathy, lupus nephritis, or polycystic kidney disease. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

  该披露提供了至少部分针对肝脏、肠道和/或肾脏的化合物，以及它们在治疗肝脏、肠道和/或肾脏疾病中的用途，如非酒精性脂肪肝、酒精性脂肪肝、肝细胞癌、肝硬化和乙型肝炎；和/或慢性肾脏疾病、肾小球疾病，如IgA肾病、狼疮性肾炎或多囊肾病。这些化合物被认为对甲硫氨酰氨肽酶2具有活性。
• COVALENT INHIBITORS OF KRAS G12C
  申请人：Araxes Pharma LLC

  公开号：US20140288045A1

  公开（公告）日：2014-09-25

  Irreversible inhibitors of G12C mutant K-Ras protein are provided. Also disclosed are methods to modulate the activity of G12C mutant K-Ras protein and methods of treatment of disorders mediated by G12C mutant K-Ras protein.

  G12C突变K-Ras蛋白的不可逆抑制剂已提供。还公开了调节G12C突变K-Ras蛋白活性的方法以及通过G12C突变K-Ras蛋白介导的疾病治疗方法。
• METHOD AND INTERMEDIATES FOR THE PREPARATION OF DERIVATIVES OF N (1-BENZHYDRYLAZETIDIN-3-YL)-N-PHENYLMETHYLSULFONAMIDE
  申请人：Boffelli Philippe

  公开号：US20070244084A1

  公开（公告）日：2007-10-18

  The invention relates to a novel method for the synthesis of N-1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide.

  这项发明涉及一种合成N-1-[双(4-氯苯基)甲基]氮杂环丙酮-3-基}-N-(3,5-二氟苯基)甲磺酰胺的新方法。
• New Compounds III
  申请人：Johansson Anders

  公开号：US20070270398A1

  公开（公告）日：2007-11-22

  The present invention relates to new compounds of formula I, to pharmaceutical compositions comprising said compounds, and to the use of said compounds in therapy. The present invention further relates to processes for the preparation of compounds of formula I.

  本发明涉及公式I的新化合物，涉及包含所述化合物的制药组合物，以及所述化合物在治疗中的用途。本发明还涉及制备公式I化合物的过程。
• Pyridyl alkene and pyridyl alkine- acid amides as cytostatics and immuno-suppressives
  申请人：Biedermann Elfi

  公开号：US20070219197A1

  公开（公告）日：2007-09-20

  The present invention relates to new pyridine compounds, methods for their production, medicaments containing these compounds as well as their use, especially in the treatment of tumor conditions and/or as cytostatic agents or as immunosuppressive agents.

  本发明涉及新的吡啶化合物，其生产方法，含有这些化合物的药物以及它们的用途，特别是在肿瘤病情的治疗中和/或作为细胞毒剂或免疫抑制剂的用途。